These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38565056)

  • 21. Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization.
    Milberg P; Frommeyer G; Uphaus T; Kaiser D; Osada N; Breithardt G; Eckardt L
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):92-100. PubMed ID: 21964157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular electropharmacology of amiodarone.
    Kodama I; Kamiya K; Toyama J
    Cardiovasc Res; 1997 Jul; 35(1):13-29. PubMed ID: 9302343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias.
    Verduyn SC; Vos MA; Leunissen HD; van Opstal JM; Wellens HJ
    J Cardiovasc Pharmacol; 1999 Feb; 33(2):212-22. PubMed ID: 10028928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
    Singh BN
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
    Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
    J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of amiodarone on short QT syndrome variant 3 in human ventricles: a simulation study.
    Luo C; Wang K; Zhang H
    Biomed Eng Online; 2017 Jun; 16(1):69. PubMed ID: 28592292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiarrhythmic effect of the Ca
    Kirchhoff JE; Diness JG; Abildgaard L; Sheykhzade M; Grunnet M; Jespersen T
    Pflugers Arch; 2016 Nov; 468(11-12):1853-1863. PubMed ID: 27722784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.
    Antzelevitch C; Belardinelli L; Zygmunt AC; Burashnikov A; Di Diego JM; Fish JM; Cordeiro JM; Thomas G
    Circulation; 2004 Aug; 110(8):904-10. PubMed ID: 15302796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sophoridine manifests as a leading compound for anti-arrhythmia with multiple ion-channel blocking effects.
    Song T; Hao Y; Wang M; Li T; Zhao C; Li J; Hou Y
    Phytomedicine; 2023 Apr; 112():154688. PubMed ID: 36738478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes.
    Bosch RF; Li GR; Gaspo R; Nattel S
    J Pharmacol Exp Ther; 1999 Apr; 289(1):156-65. PubMed ID: 10086999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
    Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ionic mechanisms of action of class III antiarrhythmic drugs].
    Kuz'min VS; Rozenshtraukh LV
    Kardiologiia; 2010; 50(7):49-61. PubMed ID: 20659045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced repolarization capacity: new potential antiarrhythmic strategy based on HERG channel activation.
    Szabó G; Farkas V; Grunnet M; Mohácsi A; Nánási PP
    Curr Med Chem; 2011; 18(24):3607-21. PubMed ID: 21774764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
    Milberg P; Ramtin S; Mönnig G; Osada N; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Pharmacol; 2004 Sep; 44(3):278-86. PubMed ID: 15475823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.